中国第一批鼓励仿制药品目录的纳入品种分析

Analysis of the First Encouraged Generic Drugs Catalogue in China

检索并整理《关于印发第一批鼓励仿制药品目录的通知》中所有品种的专利、纳入医保目录、同通用名下国产药品批文数、适应症等相关情况,探究纳入第一批鼓励仿制药品目录的药品特点,梳理我国鼓励仿制药品目录清单政策的发展,认为利匹韦林被排出的主要原因在于核心专利问题,预计此后的第二批、第三批鼓励仿制药品目录将会纳入更多专利有效期超过2年的药品;同时,随着我国专利链接制度的完善,鼓励仿制药品目录纳入品种的重点将更多集中在鼓励仿制且实际供应短缺的药品。

Search and sort out information of all drugs types from the“Notice on Issuing the First Encouraged Generic Drugs Catalogue”,including relevant patents,included in the medical insurance catalogue,numbers of domestic drug approvals under the common name,indications,and so on.Explore the drug characteristics included in the first encouraged generic drugs catalogue,and sort out the development of China's policies to encourage generic drugs catalogue,and believe that the main reason for remove ribavirin is the core patent problem.It is expected that the second and third catalogues of encouraged generic drug will include more drugs with patents valid for more than 2 years.At the same time,with the improvement of China's patent link system,the encouraging generic drug catalogue will focus more on encourage generics drugs which are in short supply.